Vakoc, C. R., Garcia-Manero, G., Look, A. T. (April 2014) Cancer therapy resistance: chasing epigenetics. Nature Medicine, 20 (4). pp. 340-341. ISSN 1078-8956
Abstract
Resistance to targeted cancer therapies is a challenge to their successful application. T cell acute lymphoblastic leukemia (T-ALL) has been found to be associated with activation of the signaling protein NOTCH1; however, clinical success of NOTCH1-targeted therapies has been transient, probably owing to the development of drug resistance. Knoechel et al.1 now identify an epigenetic mechanism of drug resistance to NOTCH-targeted therapies in T-ALL cells. Furthermore, a combination therapy of NOTCH inhibitors and a drug targeting the epigenetic mechanism was found to be effective against the resistant cells. We asked three experts how this study is likely to affect the development of further cancer therapy programs.
Item Type: | Paper |
---|---|
Subjects: | diseases & disorders > cancer diseases & disorders > cancer > drugs and therapies > chemoresistance diseases & disorders > cancer > drugs and therapies bioinformatics > genomics and proteomics > genetics & nucleic acid processing > epigenetics bioinformatics > genomics and proteomics > genetics & nucleic acid processing > DNA, RNA structure, function, modification > epigenetics |
CSHL Authors: | |
Communities: | CSHL labs > Vakoc lab |
Depositing User: | Matt Covey |
Date: | April 2014 |
Date Deposited: | 15 May 2014 19:05 |
Last Modified: | 15 May 2014 19:05 |
Related URLs: | |
URI: | https://repository.cshl.edu/id/eprint/30137 |
Actions (login required)
Administrator's edit/view item |